Hypoxia-inducible factors (HIFs) are transcription factors that regulate the cellular biological response to hypoxic stress. They regulate the expression of genes that contain hypoxia response elements (HREs), which produce proteins that coordinate to regulate biological processes including angiogenesis, proliferation, migration, and immune evasion [2]. HIFs are implicated in tumour growth and progression via their interactions with oncoproteins and tumour suppressors [1]. HIF inhibitors are in clinical development as cancer therapeutics.

1. Keith B, Johnson RS, Simon MC. (2011) HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer, 12 (1): 9-22. [PMID:22169972]

2. Majmundar AJ, Wong WJ, Simon MC. (2010) Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell, 40 (2): 294-309. [PMID:20965423]

3. Wallace EM, Rizzi JP, Han G, Wehn PM, Cao Z, Du X, Cheng T, Czerwinski RM, Dixon DD, Goggin BS et al.. (2016) A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma. Cancer Res, 76 (18): 5491-500. [PMID:27635045]

4. Xu R, Wang K, Rizzi JP, Huang H, Grina JA, Schlachter ST, Wang B, Wehn PM, Yang H, Dixon DD et al.. (2019) 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma. J Med Chem, 62 (15): 6876-6893. [PMID:31282155]